Peptide Research
Next Generation Obesity Peptides: What’s Beyond GLP-1 in 2026?
Obesity-drug research is moving beyond single-receptor GLP-1 agonism toward dual, triple and multi-target approaches that combine incretin, glucagon, amylin and other metabolic pathways. By…
